That puts Emgality ahead of Teva’s Ajovy (fremanezumab), which picked up a positive opinion from NICE earlier this year but is only recommended for use in chronic migraine sufferers who have 15 ...

An EMA advisory panel has rejected expanding the use of Eli Lilly’s Emgality to include prevention of episodic cluster headaches. The Committee for Medicinal Products for Human Use (CHMP ...

Sales of key growth products (select products launched prior to 2022 like Cyramza, Emgality, Jardiance, Olumiant, Retevmo, Taltz, Trulicity, Tyvyt and Verzenio) rose 13% to $5.95 billion.